Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Stromal Cell PD-L1 Inhibits CD8+ T-cell Antitumor Immune Responses and Promotes Colon Cancer.

O'Malley G, Treacy O, Lynch K, Naicker SD, Leonard NA, Lohan P, Dunne PD, Ritter T, Egan LJ, Ryan AE.

Cancer Immunol Res. 2018 Nov;6(11):1426-1441. doi: 10.1158/2326-6066.CIR-17-0443. Epub 2018 Sep 18. Erratum in: Cancer Immunol Res. 2019 Jan;7(1):162.

PMID:
30228206
2.

Dynamic Measures of Anxiety-Related Threat Bias: Links to Stress Reactivity.

Egan LJ, Dennis-Tiwary TA.

Motiv Emot. 2018 Aug;42(4):546-554. doi: 10.1007/s11031-018-9674-6. Epub 2018 Mar 2.

PMID:
30220752
3.

Ten Years of the Journal of Crohn's and Colitis.

Egan LJ.

J Crohns Colitis. 2017 Sep 1;11(9):1029. doi: 10.1093/ecco-jcc/jjx113. No abstract available.

PMID:
28881877
4.

Neurocognitive assessment of emotional context sensitivity.

Myruski S, Bonanno GA, Gulyayeva O, Egan LJ, Dennis-Tiwary TA.

Cogn Affect Behav Neurosci. 2017 Oct;17(5):1058-1071. doi: 10.3758/s13415-017-0533-9.

5.

Inflammation-associated DNA methylation patterns in epithelium of ulcerative colitis.

Barnicle A, Seoighe C, Greally JM, Golden A, Egan LJ.

Epigenetics. 2017 Aug;12(8):591-606. doi: 10.1080/15592294.2017.1334023. Epub 2017 May 30.

6.

Hick-Hyman Law is Mediated by the Cognitive Control Network in the Brain.

Wu T, Dufford AJ, Egan LJ, Mackie MA, Chen C, Yuan C, Chen C, Li X, Liu X, Hof PR, Fan J.

Cereb Cortex. 2018 Jul 1;28(7):2267-2282. doi: 10.1093/cercor/bhx127.

PMID:
28531252
7.

Repeated recall and PKMζ maintain fear memories in juvenile rats.

Oliver CF, Kabitzke P, Serrano P, Egan LJ, Barr GA, Shair HN, Wiedenmayer C.

Learn Mem. 2016 Nov 15;23(12):710-713. doi: 10.1101/lm.042549.116. Print 2016 Dec.

8.

Infliximab Selectively Modulates the Circulating Blood Monocyte Repertoire in Crohn's Disease.

Slevin SM, Dennedy MC, Connaughton EP, Ribeiro A, Ceredig R, Griffin MD, Egan LJ.

Inflamm Bowel Dis. 2016 Dec;22(12):2863-2878.

PMID:
27824651
9.

The Capacity of Cognitive Control Estimated from a Perceptual Decision Making Task.

Wu T, Dufford AJ, Mackie MA, Egan LJ, Fan J.

Sci Rep. 2016 Sep 23;6:34025. doi: 10.1038/srep34025.

10.

Mesenchymal stromal cells (MSCs) and colorectal cancer: a troublesome twosome for the anti-tumour immune response?

O'Malley G, Heijltjes M, Houston AM, Rani S, Ritter T, Egan LJ, Ryan AE.

Oncotarget. 2016 Sep 13;7(37):60752-60774. doi: 10.18632/oncotarget.11354. Review.

11.

Neuroanatomical Alterations in High-Functioning Adults with Autism Spectrum Disorder.

Eilam-Stock T, Wu T, Spagna A, Egan LJ, Fan J.

Front Neurosci. 2016 Jun 2;10:237. doi: 10.3389/fnins.2016.00237. eCollection 2016.

12.

Differential DNA methylation patterns of homeobox genes in proximal and distal colon epithelial cells.

Barnicle A, Seoighe C, Golden A, Greally JM, Egan LJ.

Physiol Genomics. 2016 Apr;48(4):257-73. doi: 10.1152/physiolgenomics.00046.2015. Epub 2016 Jan 26.

13.

For whom the bell tolls: Neurocognitive individual differences in the acute stress-reduction effects of an attention bias modification game for anxiety.

Dennis-Tiwary TA, Egan LJ, Babkirk S, Denefrio S.

Behav Res Ther. 2016 Feb;77:105-17. doi: 10.1016/j.brat.2015.12.008. Epub 2015 Dec 18.

14.

New Insights into the Mechanisms of Action of Anti-Tumor Necrosis Factor-α Monoclonal Antibodies in Inflammatory Bowel Disease.

Slevin SM, Egan LJ.

Inflamm Bowel Dis. 2015 Dec;21(12):2909-20. doi: 10.1097/MIB.0000000000000533. Review.

PMID:
26348448
15.

The intestinal epithelial cell cycle: uncovering its 'cryptic' nature.

McKernan DP, Egan LJ.

Curr Opin Gastroenterol. 2015 Mar;31(2):124-9. doi: 10.1097/MOG.0000000000000154. Review.

PMID:
25603403
16.

Effect of genetic deletion or pharmacological antagonism of tumor necrosis factor alpha on colitis-associated carcinogenesis in mice.

Craven B, Zaric V, Martin A, Mureau C, Egan LJ.

Inflamm Bowel Dis. 2015 Mar;21(3):485-95. doi: 10.1097/MIB.0000000000000303.

PMID:
25581824
17.

Targeting colon cancer cell NF-κB promotes an anti-tumour M1-like macrophage phenotype and inhibits peritoneal metastasis.

Ryan AE, Colleran A, O'Gorman A, O'Flynn L, Pindjacova J, Lohan P, O'Malley G, Nosov M, Mureau C, Egan LJ.

Oncogene. 2015 Mar 19;34(12):1563-74. doi: 10.1038/onc.2014.86. Epub 2014 Apr 7.

PMID:
24704833
18.

Taking a closer look at IBD.

Egan LJ, Sandborn W.

Gut. 2014 Feb;63(2):e1. doi: 10.1136/gutjnl-2013-305424. No abstract available.

PMID:
24381262
19.
20.

Gene-set analysis is severely biased when applied to genome-wide methylation data.

Geeleher P, Hartnett L, Egan LJ, Golden A, Raja Ali RA, Seoighe C.

Bioinformatics. 2013 Aug 1;29(15):1851-7. doi: 10.1093/bioinformatics/btt311. Epub 2013 Jun 3.

PMID:
23732277
21.

Gastrointestinal radiation injury: prevention and treatment.

Shadad AK, Sullivan FJ, Martin JD, Egan LJ.

World J Gastroenterol. 2013 Jan 14;19(2):199-208. doi: 10.3748/wjg.v19.i2.199. Review.

22.

Gastrointestinal radiation injury: symptoms, risk factors and mechanisms.

Shadad AK, Sullivan FJ, Martin JD, Egan LJ.

World J Gastroenterol. 2013 Jan 14;19(2):185-98. doi: 10.3748/wjg.v19.i2.185. Review.

23.

The monoacylglycerol lipase inhibitor JZL184 attenuates LPS-induced increases in cytokine expression in the rat frontal cortex and plasma: differential mechanisms of action.

Kerr DM, Harhen B, Okine BN, Egan LJ, Finn DP, Roche M.

Br J Pharmacol. 2013 Jun;169(4):808-19. doi: 10.1111/j.1476-5381.2012.02237.x.

24.

Smoking and Crohn's disease: active modification of an independent risk factor (education alone is not enough).

Kennelly RP, Subramaniam T, Egan LJ, Joyce MR.

J Crohns Colitis. 2013 Sep;7(8):631-5. doi: 10.1016/j.crohns.2012.08.019. Epub 2012 Oct 1.

PMID:
23036508
25.

Inflammation, DNA methylation and colitis-associated cancer.

Hartnett L, Egan LJ.

Carcinogenesis. 2012 Apr;33(4):723-31. doi: 10.1093/carcin/bgs006. Epub 2012 Jan 10. Review.

PMID:
22235026
26.

Pharmacological inhibition of endocannabinoid degradation modulates the expression of inflammatory mediators in the hypothalamus following an immunological stressor.

Kerr DM, Burke NN, Ford GK, Connor TJ, Harhen B, Egan LJ, Finn DP, Roche M.

Neuroscience. 2012 Mar 1;204:53-63. doi: 10.1016/j.neuroscience.2011.09.032. Epub 2011 Sep 19.

PMID:
21952131
27.

Mechanisms of drug toxicity or intolerance.

Egan LJ.

Dig Dis. 2011;29(2):172-6. doi: 10.1159/000323881. Epub 2011 Jul 5. Review.

PMID:
21734381
28.

Natural history of Crohn's disease: is the tide beginning to turn?

Maoláin MO, Egan LJ.

Ir Med J. 2011 Mar;104(3):69-70. No abstract available.

PMID:
21671517
29.

Clinical features, treatment, and survival of patients with colorectal cancer with or without inflammatory bowel disease.

Ali RA, Dooley C, Comber H, Newell J, Egan LJ.

Clin Gastroenterol Hepatol. 2011 Jul;9(7):584-9.e1-2. doi: 10.1016/j.cgh.2011.04.016. Epub 2011 Apr 22.

PMID:
21565283
30.

How to manage the risk of colorectal cancer in ulcerative colitis.

Ali RA, Egan LJ.

Curr Drug Targets. 2011 Sep;12(10):1424-32. Review.

PMID:
21466491
31.

Autophagosomal IkappaB alpha degradation plays a role in the long term control of tumor necrosis factor-alpha-induced nuclear factor-kappaB (NF-kappaB) activity.

Colleran A, Ryan A, O'Gorman A, Mureau C, Liptrot C, Dockery P, Fearnhead H, Egan LJ.

J Biol Chem. 2011 Jul 1;286(26):22886-93. doi: 10.1074/jbc.M110.199950. Epub 2011 Mar 31.

32.

The pathogen recognition receptor NOD2 regulates human FOXP3+ T cell survival.

Rahman MK, Midtling EH, Svingen PA, Xiong Y, Bell MP, Tung J, Smyrk T, Egan LJ, Faubion WA Jr.

J Immunol. 2010 Jun 15;184(12):7247-56. doi: 10.4049/jimmunol.0901479. Epub 2010 May 7.

33.

Regulation of NF-kappaB responses by epigenetic suppression of IkappaBalpha expression in HCT116 intestinal epithelial cells.

O'Gorman A, Colleran A, Ryan A, Mann J, Egan LJ.

Am J Physiol Gastrointest Liver Physiol. 2010 Jul;299(1):G96-G105. doi: 10.1152/ajpgi.00460.2009. Epub 2010 Apr 8.

34.

Upregulation of DNA methyltransferase-mediated gene silencing, anchorage-independent growth, and migration of colon cancer cells by interleukin-6.

Foran E, Garrity-Park MM, Mureau C, Newell J, Smyrk TC, Limburg PJ, Egan LJ.

Mol Cancer Res. 2010 Apr;8(4):471-81. doi: 10.1158/1541-7786.MCR-09-0496. Epub 2010 Mar 30.

35.

Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial.

Solem CA, Loftus EV Jr, Fletcher JG, Baron TH, Gostout CJ, Petersen BT, Tremaine WJ, Egan LJ, Faubion WA, Schroeder KW, Pardi DS, Hanson KA, Jewell DA, Barlow JM, Fidler JL, Huprich JE, Johnson CD, Harmsen WS, Zinsmeister AR, Sandborn WJ.

Gastrointest Endosc. 2008 Aug;68(2):255-66. doi: 10.1016/j.gie.2008.02.017. Epub 2008 Jun 2.

PMID:
18513722
36.

Risk factors for opportunistic infections in patients with inflammatory bowel disease.

Toruner M, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, Colombel JF, Egan LJ.

Gastroenterology. 2008 Apr;134(4):929-36. doi: 10.1053/j.gastro.2008.01.012. Epub 2008 Jan 11.

PMID:
18294633
37.

Gastroesophageal reflux disease in pregnancy.

Ali RA, Egan LJ.

Best Pract Res Clin Gastroenterol. 2007;21(5):793-806. Review.

PMID:
17889808
38.

Allopurinol and 6MP: steering through the therapeutic obstacle course.

Egan LJ.

Inflamm Bowel Dis. 2007 Oct;13(10):1312-3. No abstract available.

PMID:
17546679
39.

A nudge in the right direction: shaping the metabolic fate of thiopurines for therapeutic gain.

Egan LJ.

Clin Gastroenterol Hepatol. 2007 Feb;5(2):170-1. No abstract available.

PMID:
17296527
40.

Nitric oxide promotes endothelial cell survival signaling through S-nitrosylation and activation of dynamin-2.

Kang-Decker N, Cao S, Chatterjee S, Yao J, Egan LJ, Semela D, Mukhopadhyay D, Shah V.

J Cell Sci. 2007 Feb 1;120(Pt 3):492-501.

41.

NF-kappaB signaling: pros and cons of altering NF-kappaB as a therapeutic approach.

Egan LJ, Toruner M.

Ann N Y Acad Sci. 2006 Aug;1072:114-22. Review.

PMID:
17057194
42.

The AmpliChip CYP450 test: principles, challenges, and future clinical utility in digestive disease.

Juran BD, Egan LJ, Lazaridis KN.

Clin Gastroenterol Hepatol. 2006 Jul;4(7):822-30. Epub 2006 Jun 22. Review.

PMID:
16797246
43.

Pharmacogenomics in inflammatory bowel disease.

Egan LJ, Derijks LJ, Hommes DW.

Clin Gastroenterol Hepatol. 2006 Jan;4(1):21-8. Review.

PMID:
16431300
44.

Antianoikis effect of nuclear factor-kappaB through up-regulated expression of osteoprotegerin, BCL-2, and IAP-1.

Toruner M, Fernandez-Zapico M, Sha JJ, Pham L, Urrutia R, Egan LJ.

J Biol Chem. 2006 Mar 31;281(13):8686-96. Epub 2006 Jan 5.

45.

Budesonide in the treatment of inflammatory bowel disease: the first year of experience in clinical practice.

Chopra A, Pardi DS, Loftus EV Jr, Tremaine WJ, Egan LJ, Faubion WA, Hanson KA, Johnson TA, Sandborn WJ.

Inflamm Bowel Dis. 2006 Jan;12(1):29-32.

PMID:
16374255
46.

Positioning novel biologic, probiotic, and apheresis therapies for Crohn's disease and ulcerative colitis.

Egan LJ, Sandborn WJ.

Curr Gastroenterol Rep. 2005 Dec;7(6):485-91. Review.

PMID:
16313879
47.

Acute pancreatitis in patients with Crohn's disease: clinical features and outcomes.

Moolsintong P, Loftus EV Jr, Chari ST, Egan LJ, Tremaine WJ, Sandborn WJ.

Inflamm Bowel Dis. 2005 Dec;11(12):1080-4.

PMID:
16306770
48.

Endoscopic factors in the diagnosis of colorectal dysplasia in chronic inflammatory bowel disease.

Toruner M, Harewood GC, Loftus EV Jr, Sandborn WJ, Tremaine WJ, Faubion WA, Schroeder KW, Egan LJ.

Inflamm Bowel Dis. 2005 May;11(5):428-34.

PMID:
15867581
49.

Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines.

Thomas CW, Myhre GM, Tschumper R, Sreekumar R, Jelinek D, McKean DJ, Lipsky JJ, Sandborn WJ, Egan LJ.

J Pharmacol Exp Ther. 2005 Feb;312(2):537-45. Epub 2004 Sep 23.

PMID:
15388785
50.

Drug interactions in gastroenterology: mechanisms, consequences, and how to avoid.

Egan LJ.

Clin Gastroenterol Hepatol. 2004 Sep;2(9):725-30. Review.

PMID:
15354272

Supplemental Content

Support Center